Parkinson's Disease
Conditions
Keywords
Parkinson's Disease (PD), Aromatic L-Amino Acid Decarboxylase, AADC, AAV, VY-AADC02, AAV2-hAADC, DDC, Gene Therapy, Levodopa, Dopamine, Neurosurgery, NBIb-1817, Motor Fluctuations
Brief summary
The objective of this study is to assess the safety of VY-AADC02 in participants with Parkinson's disease (PD) with motor fluctuations.
Interventions
BIOLOGICALVY-AADC02
Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain
Bilateral partial burr/twist holes without dura penetration
Sponsors
Voyager Therapeutics
Neurocrine Biosciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Intervention model description
Randomized, Sham Surgery Controlled, Double-blind, Multi-center
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Males and females, 40 to 75 years of age (inclusive) 2. Diagnosis of PD, consistent with United Kingdom Brain Bank Criteria 3. Motor responsiveness to dopaminergic therapy, demonstrated by improvement in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS III score) 4. Disease duration from diagnosis of ≥4 years 5. An average of ≥3 hours of OFF time (that is, periods of insufficient control of motor PD symptoms) per day over 3 consecutive days as confirmed by the PD Diary 6. A stable, optimal regimen of Parkinson's medications including levodopa for at least weeks prior to screening evaluation. Participants must have a minimum duration of levodopa treatment of ≥1 year 7. In the judgment of the Investigator, stable Parkinson's features and symptoms for at least 4 weeks prior to screening evaluation 8. Agrees to defer any elective neurological surgery, including deep brain stimulation or ablation procedure for PD, levodopa or apomorphine infusion, or the addition of new dopaminergic formulations until after the study is completed, if medically appropriate 9. Ability to travel to study visits Key
Exclusion criteria
1. Atypical or secondary parkinsonism, including but not limited to symptoms believed to be due to trauma, brain tumor, infection, cerebrovascular disease, other neurological disease, or to drugs, chemicals, or toxins, as determined by the Investigator 2. Montreal Cognitive Assessment (MoCA) score \<26 3. New or unstable psychiatric conditions (psychosis, depression) within 1 year of screening 4. Brain imaging abnormalities in the striatum or other regions that would substantially increase risk of surgery 5. Contraindication to magnetic resonance imaging (MRI) and/or gadolinium-based contrast agents 6. Prior brain surgery, infusion therapies or planned treatments that could complicate the study procedure or negatively impact study evaluations as determined from participant interview, screening MRI, or medical records 7. History of malignancy other than treated carcinoma in situ within 3 years of screening evaluation 8. Prior gene transfer, current treatment with any investigational agent (drug or device) within 2 months of screening evaluation, or participation or plans to participate in another research study 9. Severe, biphasic and/or uncontrolled dyskinesia 10. Disabling or uncontrolled impulse control disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with treatment-emergent adverse events (TEAEs) | Up to 5 years after surgery |
Countries
United States
Outcome results
None listed